Sinaptica Therapeutics

Sinaptica Therapeutics is a clinical-stage company based in Cambridge, United States, focused on developing personalized, noninvasive therapies for Alzheimer’s disease and other neurodegenerative disorders. Their core innovation, the SinaptiStim™ System, utilizes precision neurostimulation technology to target the Default Mode Network, which plays a crucial role in memory. In a Phase 2 clinical trial, this approach demonstrated the ability to slow the progression of Alzheimer’s disease by over 80% across key cognitive and functional endpoints. The company received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2022, highlighting its innovative potential. Sinaptica is preparing to initiate a pivotal randomized controlled clinical trial in early 2025 to further assess the efficacy and safety of their therapy. Their mission is to provide safe and effective treatment options that can significantly slow cognitive decline in Alzheimer’s patients, with a design that allows for combination with existing drug therapies. Sinaptica is also part of StartUp Health’s Alzheimer’s Moonshot initiative, which supports innovative solutions to combat Alzheimer’s disease.

• Employees 16
• Founded 2021